DK2930184T3 - Dkk-1-antistoffer - Google Patents

Dkk-1-antistoffer Download PDF

Info

Publication number
DK2930184T3
DK2930184T3 DK15159780.4T DK15159780T DK2930184T3 DK 2930184 T3 DK2930184 T3 DK 2930184T3 DK 15159780 T DK15159780 T DK 15159780T DK 2930184 T3 DK2930184 T3 DK 2930184T3
Authority
DK
Denmark
Prior art keywords
dkk
antibodies
Prior art date
Application number
DK15159780.4T
Other languages
English (en)
Inventor
Marcio Chedid
Ryan James Darling
Rachelle Jeanette Galvin
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2930184T3 publication Critical patent/DK2930184T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15159780.4T 2009-04-10 2010-04-06 Dkk-1-antistoffer DK2930184T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
EP10712681.5A EP2417158B9 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (1)

Publication Number Publication Date
DK2930184T3 true DK2930184T3 (da) 2019-05-13

Family

ID=42199718

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10712681.5T DK2417158T4 (da) 2009-04-10 2010-04-06 Dkk-1-antistoffer
DK19156509.2T DK3514173T3 (da) 2009-04-10 2010-04-06 DKK-1-antistoffer
DK15159780.4T DK2930184T3 (da) 2009-04-10 2010-04-06 Dkk-1-antistoffer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10712681.5T DK2417158T4 (da) 2009-04-10 2010-04-06 Dkk-1-antistoffer
DK19156509.2T DK3514173T3 (da) 2009-04-10 2010-04-06 DKK-1-antistoffer

Country Status (30)

Country Link
US (1) US8148498B2 (da)
EP (3) EP3514173B8 (da)
JP (1) JP5759977B2 (da)
KR (3) KR20110124364A (da)
CN (1) CN102388065B (da)
AR (1) AR075989A1 (da)
AU (1) AU2010234611B2 (da)
BR (1) BRPI1014157B1 (da)
CA (1) CA2758252C (da)
CY (3) CY1119399T1 (da)
DK (3) DK2417158T4 (da)
EA (1) EA021401B1 (da)
ES (3) ES2644244T3 (da)
HR (3) HRP20171400T1 (da)
HU (3) HUE034625T2 (da)
IL (1) IL214845A (da)
LT (3) LT3514173T (da)
ME (2) ME02798B (da)
MX (1) MX2011010707A (da)
NZ (1) NZ595011A (da)
PL (3) PL3514173T3 (da)
PT (3) PT2930184T (da)
RS (3) RS56505B1 (da)
SG (1) SG175244A1 (da)
SI (3) SI3514173T1 (da)
TR (1) TR201907261T4 (da)
TW (1) TWI546079B (da)
UA (1) UA103916C2 (da)
WO (1) WO2010117980A1 (da)
ZA (1) ZA201107256B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131185A1 (en) 2009-05-12 2010-11-18 Pfizer Inc. Blocking anti-dkk-1 antibodies and their uses
MX363407B (es) 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
CA2981115C (en) * 2015-05-18 2022-05-31 Eli Lilly And Company Anti-dkk-1-anti-rankl bispecific antibody compounds
JP7525980B2 (ja) * 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Siglec-7抗体及びその使用方法
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
EP3532099A1 (en) 2016-10-26 2019-09-04 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
BR112021000427A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ctla-4
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
MX2022003396A (es) 2019-09-19 2022-04-19 Leap Therapeutics Inc Uso de inhibidores de dkk-1 para tratar el cancer.
US20240141023A1 (en) * 2019-11-22 2024-05-02 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1 inhibitors
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
EP4288098A1 (en) * 2021-02-05 2023-12-13 Omeros Corporation Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
EP4398889A1 (en) 2021-09-10 2024-07-17 Leap Therapeutics, Inc. Combination therapy
WO2024015463A1 (en) 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT975755E (pt) 1997-04-16 2007-06-26 Millennium Pharm Inc Proteínas crsp (proteínas segregadas ricas em cisteínas), moléculas de ácido nucleico que as codificam e suas utilizações
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
BR0209836A (pt) 2001-05-17 2004-12-07 Genome Therapeutics Corp Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
CA2466483A1 (en) 2001-11-07 2003-07-03 John D. Shaughnessy Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
AU2004274861A1 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
AU2005267722B2 (en) * 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2008097510A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Antibodies specific for dkk-1
BRPI1014535A2 (pt) * 2009-05-07 2016-04-05 Novatis Ag composições e métodos de uso para moléculas de ligação a dickkopf-1 ou dickkopf-4 ou ambas

Also Published As

Publication number Publication date
LT2417158T (lt) 2017-10-10
BRPI1014157A2 (pt) 2020-09-29
CA2758252A1 (en) 2010-10-14
PT2417158T (pt) 2017-10-23
CY1124412T1 (el) 2022-07-22
LT3514173T (lt) 2021-09-10
KR20140033523A (ko) 2014-03-18
HUE043904T2 (hu) 2019-09-30
HUE055376T2 (hu) 2021-11-29
SI2930184T1 (sl) 2019-06-28
MX2011010707A (es) 2012-02-28
DK2417158T4 (da) 2018-01-29
HUE034625T2 (en) 2018-02-28
CY1121637T1 (el) 2020-07-31
SI3514173T1 (sl) 2021-09-30
PL2930184T3 (pl) 2019-10-31
SG175244A1 (en) 2011-12-29
RS58612B1 (sr) 2019-05-31
HRP20171400T1 (hr) 2017-11-03
ZA201107256B (en) 2013-03-27
TWI546079B (zh) 2016-08-21
ES2728911T3 (es) 2019-10-29
ME02798B (me) 2018-01-20
DK2417158T3 (da) 2017-10-16
US8148498B2 (en) 2012-04-03
EP2417158B9 (en) 2017-12-06
EP3514173B1 (en) 2021-06-23
KR101461362B1 (ko) 2014-11-13
EP2930184B1 (en) 2019-03-27
EP2930184A1 (en) 2015-10-14
JP5759977B2 (ja) 2015-08-05
BRPI1014157B1 (pt) 2022-01-18
EP3514173A1 (en) 2019-07-24
WO2010117980A1 (en) 2010-10-14
EA201171237A1 (ru) 2012-04-30
KR20140090273A (ko) 2014-07-16
AU2010234611B2 (en) 2013-02-07
CA2758252C (en) 2015-02-24
JP2012523417A (ja) 2012-10-04
RS56505B1 (sr) 2018-02-28
PT3514173T (pt) 2021-08-16
HRP20190643T1 (hr) 2019-05-31
AU2010234611A1 (en) 2011-10-20
RS62214B1 (sr) 2021-09-30
EP2417158B1 (en) 2017-08-02
IL214845A0 (en) 2011-11-30
UA103916C2 (en) 2013-12-10
PL2417158T3 (pl) 2017-12-29
IL214845A (en) 2016-06-30
LT2930184T (lt) 2019-05-10
TR201907261T4 (tr) 2019-06-21
EP2417158A1 (en) 2012-02-15
EP3514173B8 (en) 2021-08-04
PT2930184T (pt) 2019-06-17
KR20110124364A (ko) 2011-11-16
ES2644244T3 (es) 2017-11-28
TW201100101A (en) 2011-01-01
CN102388065B (zh) 2014-09-03
HRP20211343T1 (hr) 2021-11-26
EA021401B1 (ru) 2015-06-30
DK3514173T3 (da) 2021-08-02
SI2417158T1 (sl) 2017-10-30
US20100260754A1 (en) 2010-10-14
NZ595011A (en) 2013-05-31
CY1119399T1 (el) 2018-02-14
ME03378B (me) 2020-01-20
PL3514173T3 (pl) 2022-01-17
CN102388065A (zh) 2012-03-21
ES2887176T3 (es) 2021-12-22
AR075989A1 (es) 2011-05-11

Similar Documents

Publication Publication Date Title
HRP20171400T1 (hr) Protutijela protiv dkk-1
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
BRPI1011005A2 (pt) anticorpos anti-epcam
DK2414015T3 (da) Laryngoskopsystem
FI20096350A (fi) Tuloilmalaite
DK2517018T3 (da) Biomarkører
FI20095409A0 (fi) Soluviljelysupplementti
FI20095139A0 (fi) Kaasukasvatusreaktori
FI20096331A0 (fi) Antibodin käyttö
TH0901003923A (th) แอนติบอดีหลายความจำเพาะ
TH0901003733A (th) องค์ประกอบเชิงภูมิคุ้มกัน
FI8667U1 (fi) Seulakauha
FI8599U1 (fi) Nutturavyö
FI8497U1 (fi) Jätekippain
FI8438U1 (fi) Osastoija
FIU20100243U0 (fi) Kantoteline
FIU20090448U0 (fi) Klapuapu
FI20095898A0 (fi) Kuivajääpuhallin
FI20096102A (fi) Hirsirakenne
FI20095114A0 (fi) Kuorintalementti
FI20090497A0 (fi) Myyräpyydys
FI20090457A0 (fi) Tuuliluokitin
FI20090400A0 (fi) Saksilava
FI20090164A0 (fi) Elementtikarsina
FI20090102A0 (fi) Etänäytönohjainmenetelmä